S'abonner

Neuroinflammation in Alzheimer’s disease - 17/03/15

Doi : 10.1016/S1474-4422(15)70016-5 
Michael T Heneka, ProfMD a, b, , Monica J Carson, ProfPhD c, Joseph El Khoury, ProfMD d, Gary E Landreth, ProfPhD e, Frederic Brosseron, PhD b, Douglas L Feinstein, ProfPhD f, Andreas H Jacobs, ProfMD g, h, Tony Wyss-Coray, ProfPhD i, j, Javier Vitorica, ProfPhD k, Richard M Ransohoff, ProfMD l, Karl Herrup, ProfPhD m, Sally A Frautschy, ProfPhD n, Bente Finsen, ProfMD o, Guy C Brown, ProfPhD p, Alexei Verkhratsky, ProfMD q, r, s, Koji Yamanaka, ProfMD t, Jari Koistinaho, ProfMD u, Eicke Latz, ProfMD b, v, w, Annett Halle, MD x, Gabor C Petzold, ProfMD a, b, Terrence Town, ProfPhD y, Dave Morgan, ProfPhD z, Mari L Shinohara, ProfPhD aa, V Hugh Perry, ProfPhD ab, Clive Holmes, ProfPhD ac, ad, Nicolas G Bazan, ProfMD ae, David J Brooks, ProfMD af, Stéphane Hunot, PhD ag, Bertrand Joseph, ProfPhD ah, Nikolaus Deigendesch, MD ai, Olga Garaschuk, ProfPhD aj, Erik Boddeke, ProfPhD ak, Charles A Dinarello, ProfMD al, John C Breitner, ProfMD am, Greg M Cole, ProfPhD n, Douglas T Golenbock, ProfMD w, Markus P Kummer, PhD a
a Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany 
b German Center for Neurodegnerative Diseases (DZNE), Bonn, Germany 
c Division of Biomedical Sciences, Center for Glial-Neuronal Interactions, University of California, Riverside, CA, USA 
d Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 
e Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA 
f Department of Anesthesiology, University of Illinois, Chicago, IL, USA 
g Department of Geriatrics, Johanniter Hospital, Bonn, Germany 
h European Institute for Molecular Imaging (EIMI) at the Westfalian Wilhelms University (WWU), Münster, Germany 
i Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA 
j Center for Tissue Regeneration, Repair, and Restoration, VA Palo Alto Health Care System, Palo Alto, CA, USA 
k Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocio, Consejo Superior de Investigaciones Cientificas Universidad de Sevilla, Sevilla, Spain 
l Department of Neuroscience, Neuroinflammation Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA 
m Division of Life Science, Hong Kong University of Science and Technology, Hong Kong 
n Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, the Geriatric, Research, and Clinical Center, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA 
o Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark 
p Department of Biochemistry, University of Cambridge, Cambridge, UK 
q Faculty of Life Sciences, The University of Manchester, Manchester, UK 
r Achucarro Center for Neuroscience, Basque Foundation for Science (IKERBASQUE), Bilbao, Spain 
s Department of Neurosciences, University of the Basque Country UPV/EHU (Euskal Herriko Unibertsitatea/Universidad del País Vasco) and CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), Leioa, Spain 
t Research Institute of Environmental Medicine, Nagoya University/RIKEN Brain Science Institute, Wako-shi, Japan 
u Department of Neurobiology, AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland 
v Institute of Innate Immunity, University of Bonn, Bonn, Germany 
w Department of InfectiousDiseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA 
x Max-Planck Research Group Neuroimmunology, Center of Advanced European Studies and Research (CAESAR), Bonn, Germany 
y Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA 
z Department of Molecular Pharmacology and Physiology, Byrd Alzheimer’s Institute, University of South Florida College of Medicine, Tampa, FL, USA 
aa Department of Immunology, Duke University Medical Center, Durham, NC, USA 
ab School of Biological Sciences, Southampton General Hospital, Southampton, UK 
ac Clinical and Experimental Science, University of Southampton, Southampton, UK 
ad Memory Assessment and Research Centre, Moorgreen Hospital, Southern Health Foundation Trust, Southampton, UK 
ae Louisiana State University Neuroscience Center of Excellence, Louisiana State University Health Sciences Center School of Medicine in New Orleans, LA, USA 
af Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK 
ag Centre National de la Recherche Scientifique (CNRS), UMR 7225, Experimental Therapeutics of Neurodegeneration, Paris, France 
ah Department of Oncology Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden 
ai Department of Cellular Microbiology, Max Planck Institute for Infection Biology, Berlin, Germany 
aj Institute of Physiology II, Eberhard Karls University of Tübingen, Tübingen, Germany 
ak Department of Neuroscience, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands 
al Department of Medicine, University of Colorado Denver, Aurora, CO, USA 
am Centre for Studies on Prevention of Alzheimer’s Disease, Douglas Mental Health University Institute, and the McGill University Faculty of Medicine, Montreal, Quebec, Canada 

* Correspondence to: Prof Michael T Heneka, Department of Neurology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany

Summary

Increasing evidence suggests that Alzheimer’s disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer’s disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer’s disease.

Le texte complet de cet article est disponible en PDF.

Plan


© 2015  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 14 - N° 4

P. 388-405 - avril 2015 Retour au numéro
Article précédent Article précédent
  • Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis
  • Luciano A Sposato, Lauren E Cipriano, Gustavo Saposnik, Estefanía Ruíz Vargas, Patricia M Riccio, Vladimir Hachinski
| Article suivant Article suivant
  • Role of the innate and adaptive immune responses in the course of multiple sclerosis
  • Bernhard Hemmer, Martin Kerschensteiner, Thomas Korn

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.